MariMedMRMD -3.57% FCF Yield % is 18.87 as of Jun. 27, 2026. The stock has 5 warning signs investors should review. Among 1,005 Drug Manufacturers companies, MariMed ranks better than 94.63% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
MariMed FCF Yield % Related Terms
MariMed FCF Yield % Historical Data
* Premium members only.
The historical data trend for MariMed's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MariMed FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, MariMed's FCF Yield % distribution charts can be found below:
* The bar in red indicates where MariMed's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MariMed (MRMD) has a FCF Yield % of 18.87 as of Jun. 27, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MariMed and its competitors. According to the industry distribution chart, MariMed ranks #54 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is MariMed's FCF Yield % too high?
MariMed's current FCF Yield % is 18.87. The Drug Manufacturers industry median FCF Yield % is 0.67. MariMed's value of 18.87 is 2716.4% above this industry median. Based on the distribution chart, MariMed ranks #54 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does MariMed's FCF Yield % compare to CPHI and RMTI?
According to the Drug Manufacturers industry distribution chart, MariMed ranks #54 out of 1005 companies for FCF Yield %. This places MariMed in the top 5% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. MariMed's value of 18.87 is 2716.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MariMed's current FCF Yield % of 18.87 is 2716.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on MariMed and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MariMed's current FCF Yield % is 18.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MariMed stock overvalued right now?
Based on GuruFocus' analysis, MariMed (MRMD) is currently considered Possible Value Trap. The stock's GF Value™ is $0.16, compared to a current price of $0.07 — trading 56.1% below its estimated fair value. The current FCF Yield % is 18.87 and 2716.4% above the Drug Manufacturers industry median of 0.67. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For MariMed (MRMD), the current FCF Yield % is 18.87 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MariMed Inc is a multi-state cannabis operator in the United States dedicated to improving lives every day through its high-quality products. The company develops, owns, and manages seed to sale state-licensed, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis. It has created and continues to develop its own brands of cannabis flower, concentrates, edibles, and other precision-dosed products utilizing its proprietary strains and formulations. The company also licenses its proprietary brands, along with other top cannabis products, in select domestic markets. Its operations are conducted in compliance with applicable state and local laws and regulations in the jurisdictions in which it operates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRMD has been successfully added to your 